Cargando…
Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer
In metastatic or locally advanced urothelial carcinoma (UC), therapeutic options have been limited to chemotherapy and immune checkpoint inhibitors. Novel targets and drugs such as antibody drug conjugates have been developed, and enfortumab vedotin targeting nectin-4 and sacituzumab govitecan (SG)...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644361/ https://www.ncbi.nlm.nih.gov/pubmed/38020299 http://dx.doi.org/10.3892/ol.2023.14114 |
_version_ | 1785134531173416960 |
---|---|
author | Abbas, Mahmoud Heitplatz, Barbara Bernemann, Christof Boegemann, Martin Trautmann, Marcel Schrader, Andres Jan Wardelmann, Eva Schlack, Katrin |
author_facet | Abbas, Mahmoud Heitplatz, Barbara Bernemann, Christof Boegemann, Martin Trautmann, Marcel Schrader, Andres Jan Wardelmann, Eva Schlack, Katrin |
author_sort | Abbas, Mahmoud |
collection | PubMed |
description | In metastatic or locally advanced urothelial carcinoma (UC), therapeutic options have been limited to chemotherapy and immune checkpoint inhibitors. Novel targets and drugs such as antibody drug conjugates have been developed, and enfortumab vedotin targeting nectin-4 and sacituzumab govitecan (SG) targeting trophoblast cell surface antigen 2 (TROP-2), the protein product of the TACSTD2 gene, have been approved. The expression of TROP-2 was investigated within UC and other types of carcinomas, and within the tissue of different healthy organs to understand treatment responses and toxicities. The expression of TROP-2 in the tissues of 42 patients with UC, 13 patients with other types of cancer and in the normal tissues of 11 patients was retrospectively analyzed. Immunohistochemical staining of the TROP-2 protein was performed on a BenchMark ULTRA IHC/ISH System (Roche Tissue Diagnostics; Roche Diagnostics, Ltd.) according to accredited staining protocols in a routine immunohistochemistry accredited and certified facility of the laboratory of immunohistochemistry at the Institute of Pathology (Gerhard-Domagk Institute)- University Hospital Muenster (UKM)-Muenster-Germany]. Different expression levels of TROP-2 were observed, and the highest expression rate of TROP-2 was observed in UC, independent of the tumor stage. However, normal urothelial cells had similar expression levels. Except for ductal carcinoma in situ, the expression of TROP-2 was reduced in other types of cancer and in the healthy tissues from other organs, including pancreas, gall bladder, colon and prostate. Given the treatment response based on the expression level of TROP-2, SG would be effective in almost all cases of UC. However, it would also have an effect on the normal urothelium. |
format | Online Article Text |
id | pubmed-10644361 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-106443612023-10-23 Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer Abbas, Mahmoud Heitplatz, Barbara Bernemann, Christof Boegemann, Martin Trautmann, Marcel Schrader, Andres Jan Wardelmann, Eva Schlack, Katrin Oncol Lett Articles In metastatic or locally advanced urothelial carcinoma (UC), therapeutic options have been limited to chemotherapy and immune checkpoint inhibitors. Novel targets and drugs such as antibody drug conjugates have been developed, and enfortumab vedotin targeting nectin-4 and sacituzumab govitecan (SG) targeting trophoblast cell surface antigen 2 (TROP-2), the protein product of the TACSTD2 gene, have been approved. The expression of TROP-2 was investigated within UC and other types of carcinomas, and within the tissue of different healthy organs to understand treatment responses and toxicities. The expression of TROP-2 in the tissues of 42 patients with UC, 13 patients with other types of cancer and in the normal tissues of 11 patients was retrospectively analyzed. Immunohistochemical staining of the TROP-2 protein was performed on a BenchMark ULTRA IHC/ISH System (Roche Tissue Diagnostics; Roche Diagnostics, Ltd.) according to accredited staining protocols in a routine immunohistochemistry accredited and certified facility of the laboratory of immunohistochemistry at the Institute of Pathology (Gerhard-Domagk Institute)- University Hospital Muenster (UKM)-Muenster-Germany]. Different expression levels of TROP-2 were observed, and the highest expression rate of TROP-2 was observed in UC, independent of the tumor stage. However, normal urothelial cells had similar expression levels. Except for ductal carcinoma in situ, the expression of TROP-2 was reduced in other types of cancer and in the healthy tissues from other organs, including pancreas, gall bladder, colon and prostate. Given the treatment response based on the expression level of TROP-2, SG would be effective in almost all cases of UC. However, it would also have an effect on the normal urothelium. D.A. Spandidos 2023-10-23 /pmc/articles/PMC10644361/ /pubmed/38020299 http://dx.doi.org/10.3892/ol.2023.14114 Text en Copyright: © Abbas et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Abbas, Mahmoud Heitplatz, Barbara Bernemann, Christof Boegemann, Martin Trautmann, Marcel Schrader, Andres Jan Wardelmann, Eva Schlack, Katrin Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer |
title | Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer |
title_full | Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer |
title_fullStr | Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer |
title_full_unstemmed | Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer |
title_short | Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer |
title_sort | immunohistochemical expression of trop‑2 (tacstd2) on the urothelial carcinoma of the urinary bladder and other types of cancer |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644361/ https://www.ncbi.nlm.nih.gov/pubmed/38020299 http://dx.doi.org/10.3892/ol.2023.14114 |
work_keys_str_mv | AT abbasmahmoud immunohistochemicalexpressionoftrop2tacstd2ontheurothelialcarcinomaoftheurinarybladderandothertypesofcancer AT heitplatzbarbara immunohistochemicalexpressionoftrop2tacstd2ontheurothelialcarcinomaoftheurinarybladderandothertypesofcancer AT bernemannchristof immunohistochemicalexpressionoftrop2tacstd2ontheurothelialcarcinomaoftheurinarybladderandothertypesofcancer AT boegemannmartin immunohistochemicalexpressionoftrop2tacstd2ontheurothelialcarcinomaoftheurinarybladderandothertypesofcancer AT trautmannmarcel immunohistochemicalexpressionoftrop2tacstd2ontheurothelialcarcinomaoftheurinarybladderandothertypesofcancer AT schraderandresjan immunohistochemicalexpressionoftrop2tacstd2ontheurothelialcarcinomaoftheurinarybladderandothertypesofcancer AT wardelmanneva immunohistochemicalexpressionoftrop2tacstd2ontheurothelialcarcinomaoftheurinarybladderandothertypesofcancer AT schlackkatrin immunohistochemicalexpressionoftrop2tacstd2ontheurothelialcarcinomaoftheurinarybladderandothertypesofcancer |